Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Serum tissue factor pathway inhibitor 2 (TFPI2) shows promise as a diagnostic marker for endometrial cancer, aiding in diagnosis and prognosis prediction. Further trials are needed to confirm its clinical utility.
Area Of Science
- Gynecologic Oncology
- Biomarker Discovery
- Cancer Diagnostics
Background
- Endometrial cancer lacks a reliable blood diagnostic biomarker.
- Tissue factor pathway inhibitor 2 (TFPI2), a known ovarian cancer marker, was investigated for endometrial cancer utility.
Purpose Of The Study
- To evaluate serum TFPI2 as a diagnostic marker for endometrial cancer.
- To assess the correlation between serum and tissue TFPI2 levels and their prognostic value.
Main Methods
- Serum TFPI2 levels were measured in endometrial cancer patients (n=328) and healthy controls (n=65).
- Immunohistochemistry (IHC) assessed TFPI2 expression in tumor tissues (n=105).
- Clinicopathological characteristics and survival rates were analyzed in relation to TFPI2 levels.
Main Results
- Serum TFPI2 levels were significantly higher in endometrial cancer patients (196.7 pg/mL) vs. controls (83.3 pg/mL).
- TFPI2 demonstrated 54.3% sensitivity and 95.4% specificity, with levels increasing with disease stage and high-risk histology.
- TFPI2 positivity correlated with worse 5-year survival (HR 8.22) but showed poor agreement with tissue expression.
Conclusions
- Serum TFPI2 is a potential biomarker for endometrial cancer diagnosis and prognosis.
- Serum and tissue TFPI2 levels are not correlated.
- Multicenter trials are recommended to validate TFPI2's diagnostic role.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.